Fingerprint
Dive into the research topics of 'Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer
Bruce E. Johnson, Pasi A. Jänne, Jeffrey Engelman, John Heymach, David Johnson, Glenwood Goss, Thomas Lynch
Research output: Contribution to journal › Article › peer-review
36
Scopus
citations